Cytokinetics amends bylaws to strengthen stockholder meeting and proxy procedures

CYTOKINETICS INC

Requires director nominees under universal proxy rules to comply with SEC rules and provide evidence.
Enhances advance notice disclosures: stockholders must provide background info on nominees and interested persons.
Mandates that soliciting stockholders use a proxy color other than white.
Clarifies Board's ability to adjourn or postpone stockholder meetings.
Conforms provisions to Delaware General Corporation Law; includes administrative updates.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CYTOKINETICS INC: Amended and restated bylaws to update advance notice provisions, universal proxy rule compliance, proxy color requirement, stockholder meeting conduct, and conform to Delaware law (effective 2023-11-16).

Change: bylaw amendment
Effective: 2023-11-16

Exact text from the filing

On and effective as of November 16, 2023, the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) approved and adopted an amendment and restatement of the Amended and Restated Bylaws of the Company (as so amended and restated, the “Revised Bylaws”)

View on SEC.gov

31 governance changes filed in the last 30 days. Browse all governance changes →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-064829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.